Belgium (BE)

CyberGlove for clinical use? (2021) Michaelis J, Reiher I, Heinrich S, Coppers B, Schett G, Kleyer A, Elewaut D, et al. Conference contribution, Abstract of a poster Adjuvant Chemotherapy for Muscle-invasive Bladder Cancer: A Systematic Review and Meta-analysis of Individual Participant Data from Randomised Controlled Trials (2021) Burdett S, Fisher DJ, Vale CL, Bono AV, Clarke NW, Cognetti F, Collette L, et al. Journal article, Review article Modeling dysphonia severity as a function of roughness and breathiness ratings in the GRBAS scale (2021) Ferrer CA, Aragón E, Hdez-Díaz ME, De Bodt MS, Cmejla R, Englert M, Behlau M, Nöth E Conference contribution Safety and efficacy of combining biologics or small molecules for inflammatory bowel disease or immune-mediated inflammatory diseases: A European retrospective observational study (2021) Goessens L, Colombel JF, Outtier A, Ferrante M, Sabino J, Judge C, Saeidi R, et al. Journal article The EANM guideline for radiosynoviorthesis (2021) Kampen WU, Boddenberg-Paetzold B, Fischer M, Gabriel M, Klett R, Konijnenberg M, Kresnik E, et al. Journal article A Survey on Mixed-Integer Programming Techniques in Bilevel Optimization (2021) Kleinert T, Labbe M, Ljubic I, Schmidt M Journal article Physicians' Opinion and Practice With the Continuous Use of Sedatives in the Last Days of Life (2021) Heijltjes MT, Morita T, Mori M, Heckel M, Klein C, Stiel S, Miccinesi G, et al. Journal article Association of quality of life (QOL) with overall survival (OS) in patients (pts) with HR+/HER2-advanced breast cancer (ABC) treated with ribociclib (RIB) plus endocrine therapy (ET) in the MONALEESA-3 (ML-3) and ML-7 trials (2021) Fasching P, Harbeck N, Jerusalem G, Colleoni MA, Neven P, Franke F, De Laurentiis M, et al. Conference contribution The phase III NETTER-1 study of 177Lu-DOTATATE in patients with midgut neuroendocrine tumours: Further survival analyses (2021) Ruszniewski PB, Caplin ME, Kunz PL, Bodei L, Hendifar AE, Mittra E, Wolin EM, et al. Conference contribution PACIFIC-R real-world study: Treatment duration and interim analysis of progression-free survival in unresectable stage III NSCLC patients treated with durvalumab after chemoradiotherapy (2021) Girard N, Smit HJM, Sibille A, Mcdonald F, Mornex F, Garassino MCC, Filippi AR, et al. Conference contribution